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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To review the effects of chlorpromazine compared with thiothixene for people with schizophrenia.
B A C K G R O U N D
Description of the condition
Schizophrenia is a chronic and disabling mental illness. Its symp-
toms include, but are not limited to, cognitive impairment, delu-
sions (fixed beliefs that are not amenable to change in light of
conflicting evidence) (Tandon 2013), and hallucinations (sensory
perception that has the compelling sense of reality of a true percep-
tion) (Owen 2016). A previous systematic review found the inci-
dence of schizophrenia diagnosis to be between 0.5% to 1% of the
global population (McGrath 2004). Furthermore, its age of onset
is usually between 15 and 30 years old (Sham 1994). The cause of
schizophrenia remains unclear with a multitude of genetic and en-
vironmental factors being postulated to be the underlying genesis
of the heterogeneous symptomology of this disorder. People with
a genetic predisposition have a higher risk for schizophrenia (Goff
2016; Owen 2016). Half of all people with the illness have long-
term disability and for about one in five people the symptoms will
be chronic (Barbato 1998). Adding to this, depression is found in
half of those with schizophrenia, one in three experience comorbid
post-traumatic stress disorder, and one in four have comorbid ob-
sessive-compulsive disorder (Buckley 2009). Life expectancy is 10
to 20 years below the norm (Chesney 2014). The World Health
Organization (WHO) ranks schizophrenia as the ninth most bur-
densome illness globally (Deshpande 2016;WHO 2011). In Eng-
land alone, the price of clinical healthcare and social community
care is believed to be GBP 11.8 billion annually (Schizophrenia
Commission 2012).
Description of the intervention
First-line treatment options for schizophrenia are use of antipsy-
chotic medications, combined with psychological therapy and
community support (Owen 2016). These medications, perhaps
chlorpromazine in particular, have revolutionised the care of peo-
ple with schizophrenia by effectively treating the core symptoms
of this illness (Turner 2007). There are many antipsychotic drugs,
old and new, available for the treatment of schizophrenia. With
80% of the world’s population of people (therefore, 80% of those
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with schizophrenia) living in low- to middle-income countries,
inexpensive treatments are important to fully appraise; with, per-
haps, the benefit of also helping wealthier care cultures not to for-
get valuable treatments (Adams 2005; WHO 2011).
Chlorpromazinewas developed in 1951by scientist PaulCharpen-
tier, and was not created intentionally as an antipsychotic (Meyer
1997). Instead its primary purpose was to aid anaesthesia and pre-
vent people from going into surgical shock (Hamon 1952). Re-
searchers discovered that it was a multifunctional medication (so it
has a commercial name of Largactil [large-act-ill]) (Bryan 2011),
and that one of these functions was to affect psychotic symptoms.
Chlorpromazine was the first antipsychotic medication available
to people with schizophrenia who would have previously been
treated with sedatives, such as bromides and barbiturates (Ban
2007; Turner 2007). Due to the success of chlorpromazine, many
were able to be discharged and live lives largely outside of hospital
(Bryan 2011). Chlorpromazine seemed able to stabilise symptoms
of schizophrenia, especially delusions, hallucinations, and disor-
ganisation in thought and behaviour (Meyer 1997). The success
of chlorpromazine led the way for other antipsychotic medications
to be manufactured (López-Muñoz 2005), and remains a medica-
tion of choice for many clinicians worldwide as it is listed on the
WHO essential drugs list (WHO 2015).
Thiothixene is an antipsychotic from a different drug ‘family’
(thioxanthenes with anticholinergic properties as opposed to phe-
nothiazine family of chlorpromazine), which was introduced to
the market in 1967 under the trade name of Navane by the phar-
maceutical company Pfizer (FDA 2016). Thiothixene is consid-
ered to be more potent than chlorpromazine (Leung 2015), and
has been found to cause extrapyramidal symptoms (hand tremor,
gait disturbances,muscle stiffness), anticholinergic effects (blurred
vision, dry mouth), and neuroleptic malignant syndrome (Chew
2009; Karimi 2014). Although the use of thiothixene has sig-
nificantly declined in recent decades, with newer antipsychotics
such as risperidone being favoured by those who prescribe antipsy-
chotics (NCBI 2016a), thiothixine continues to be manufactured
and licensed in several countries (Table 1; Table 2).
How the intervention might work
The antipsychotic effects of chlorpromazine and thiothixene seem
to be due to their action as an antagonist (blocking agent) at the
dopamine receptors (D2) of the mesolimbic pathway, reducing
the absorption of excess dopamine (Bryan 2011; Howes 2009;
Weaver 2015).
Chlorpromazine (2-chloro-10-
(3-dimethylaminopropyl)phenothiazine) (Figure 1; Figure 2) is an
antipsychotic drug of the phenothiazine series, and acts as an an-
tagonist at D1 and D2 receptors (Seeman 1987). Chlorpromazine
also produces effects in the central nervous system (principally at
subcortical levels), has powerful antiadrenergic properties, and to
a lesser extent antihistaminic, anticholinergic, and antiserotonin
properties (NCBI 2016b). Due to its minor effect as a presynaptic
inhibitor of dopamine reuptake, chlorpromazine may act to re-
duce depression and parkinsonism (Wishart 2006).
Figure 1. Chlorpromazine: (2-chloro-10-(3-dimethylaminopropyl)phenothiazine)
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Figure 2. Chlorpromazine: (2-chloro-10-(3-dimethylaminopropyl)phenothiazine)
Thiothixene ((9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-
yl)propylidene]thioxanthene-2-sulfonamide) (Figure 3) acts as an
antagonist by targeting the D1, D2, D3, and D4 dopamine re-
ceptors, 5-HT1 and 5-HT2 serotonin receptors, H1 histaminer-
gic receptors, alpha-adrenergic receptors, and the cholinergic M1/
M2-receptors (Wishart 2006). Dopamine turnover is increased in
response to thiothixene’s action as an antagonist at the somatoden-
dritic autoreceptor (NCBI 2016a). Additionally, thiothixene is an
antiemetic; its effect of decreasing dopamine receptor activity in
turn reduces activity of the vomiting centre in the brain (NCBI
2016a).
Figure 3. Thiothixine: (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-
sulfonamide)
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Why it is important to do this review
Chlorpromazine and thiothixine are two antipsychotic medica-
tions used to treat people with schizophrenia. It is important to
know if one drug offers an advantage over another in order to
provide the optimal care for patients. As far as we understand
these medications enjoy markedly different market exposure and
should the less-widely distributed thiothixene have advantage over
chlorpromazine, this would be important to know. We know of
no up-to-date systematic reviews that directly compare these two
antipsychotic drugs. This Cochrane Review is one of a series of
reviews in order to evaluate chlorpromazine in comparison with
other antipsychotics so that a full overview of chlorpromazine’s
clinical efficacy can be completed (Table 3).
O B J E C T I V E S
To review the effects of chlorpromazine comparedwith thiothixene
for people with schizophrenia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all relevant randomised controlled trials (RCTs).
We will include trials that are described as ’double blind’, in which
randomisation is implied, in a sensitity analysis ( Sensitivity
analysis’ section). We will exclude quasi-randomised studies, such
as those that allocate intervention by alternate days of the week.
Types of participants
We will include studies where at least 80% of their participants
are aged 18 to 65 years old (representing the adult population in
the mental healthcare services) and have a primary diagnosis of
schizophrenia by any means of diagnosis (for inclusion no fewer
than 60% of the participants in the trial must have schizophrenia).
We will not include trials that include people with dual diagnosis.
We wish to ensure that we identify information that is as rele-
vant as possible to the current care of people with schizophrenia.
Therefore, we will aim, if possible, to highlight the current clinical
state clearly (acute, early post-acute, partial remission, remission),
as well as the stage (prodromal, first episode, early illness, persis-
tent), and whether the studies primarily focused on people with
particular problems (e.g. negative symptoms, treatment-resistant
illnesses).
Types of interventions
1. Chlorpromazine: any dose, in any form (standard dose
ranges are 75 mg to 300 mg)
Brand names: Anadep, Cain, Chloractil, Chlorazin, Chlorec-
til Plus, Chlorprol, Chlorpromados, Chlorpromanyl, Chlor-
promezets, Chlor-PZ, Clozine Forte, Clozine Plus, Cromedazine,
Elmarine, Emetil, Emetil-DS, Emetil Plus, Esmind, Fenactil,
Hibanil, Hibernal, Klorazine, klorproman, Klorpromex, Lacalm
Forte, Largactil, Megaphen, Megatil, Neurazine, Onazine, Plego-
mazine, Procalm, Promachel, Promachlor, Promacid, Promapar,
Promexin, Promexy-HF, Prophaphenin, Prozil, Psychozine, Psy-
laktil, Reliclam Forte, Reliclam-SF, Relitil, Scrazone, Ser, Serectil,
Sonazine, Sun Prazin, Thoradex, Thorazine, Tranzine, Trinicalm
forte, and Zinetil.
2. Thiothixine: any dose, in any form (standard dose ranges
are 20 mg to 60 mg)
Brand names: Navane, Orbinamon, Navaron, and Tiotixene (inn/
usan).
Types of outcome measures
We will, where possible, categorise outcomes as either short- (zero
to eight weeks), medium- (two to six months), or long-term (six
months to two years).
We will endeavour to report binary outcomes recording clear and
clinically meaningful degrees of change (e.g. global impression of
much improved, or more than 50% improvement on a rating scale
- as defined within the trials) before any others. Thereafter we will
list other binary outcomes and then those that are continuous.
Primary outcomes
1. Global state
1.1 Clinically important overall change, as defined by individual
trials
2. Mental state
2.1 General: clinically important overall change, as defined by
individual trials
3. Adverse effects
3.1 Specific: movement disorders (such as extrapyramidal side ef-
fects, specifically tardive dyskinesia, and neuroleptic malignant
syndrome) - clinically important overall change, as defined by in-
dividual trials
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Secondary outcomes
1. Global state
1.1 Relapse, as defined by each study
1.2 Any change in global state
1.3 Average endpoint or change score global state scale
2. Mental state
2.1 General
2.1.1 Any change in overall mental state, as defined by each of the
studies
2.1.2 Average endpoint or change score on overall mental state
scale
2.2 Specific (e.g. positive, negative, affective, cognitive
symptoms of schizophrenia)
2.2.1Clinically important change in specific symptoms, as defined
by each of the studies
2.2.2 Any change in specific symptoms, as defined by each of the
studies
2.2.3 Average endpoint or change score specific symptom scale
3. Adverse effects
3.1 General adverse effects
3.1.1 At least one adverse effect
3.1.2 Average endpoint/change scores adverse-effect scales
3.2 Specific adverse effects: clinically important, as defined by
each of the studies
3.2.1 Anticholinergic
3.2.2 Cardiovascular
3.2.3 Central nervous system
3.2.4 Gastrointestinal
3.2.5 Endocrine (e.g. amenorrhoea, galactorrhoea, hyperlipi-
daemia, hyperglycaemia, hyperinsulinaemia)
3.2.6 Haematology (e.g. haemogram, leukopenia, agranulocyto-
sis/neutropenia)
3.2.7 Hepatic (e.g. abnormal transaminase, abnormal liver func-
tion)
3.2.8 Metabolic
3.2.9 Movement disorders (other than primary outcome effects)
3.2.10 Various other
3.2.11 Death - suicide and natural causes
4. Service use
4.1 Hospital admission/re-admission
4.2 Duration of hospital stay
5. Leaving the study early
5.1 Any reason
5.2 Specific reasons
6. Behaviour
6.1 General behaviour
6.1.1 Clinically important change overall behaviour, as defined by
individual trials
6.1.2 Average endpoint/change scores general behaviour scale
6.2 Specific behaviours
6.2.1 Aggressive or violent behaviour
7. Functioning
7.1 Clinically important change in specific aspects of functioning,
such as life skills or social functioning, as defined by each of the
studies
7.2 Any change in specific aspects of functioning, such as life skills
or social functioning, as defined by each of the studies
7.3 Average endpoint or change score nonspecific aspects of func-
tioning scale, such as life skills or social functioning, as defined by
each of the studies
7.4 Any change in employment status (employed/unemployed)
during trial, as defined by each study.
8. Satisfaction with care (recipients of care or carers)
(including subjective well-being and family burden)
8.1 Recipient
8.1.1 Clinically important change in satisfaction, as defined by
each of the studies
8.1.2 Recipient of care satisfied/not satisfied with treatment
8.1.3 Recipient of care average endpoint or change score on satis-
faction scale
8.2 Carers (including health professionals)
8.2.1 Clinically important change in satisfaction, as defined by
each of the studies
8.2.2 Carer satisfied/not satisfied with treatment (general impres-
sion of carer/other)
8.2.3 Carer average endpoint or change score on satisfaction scale
9. Economic outcomes
9.1 Costs due to treatment, as defined by each study
9.2 Total direct and indirect costs
9.3 Average change in total cost of medical and mental health care
’Summary of findings’ table
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We will use the GRADE approach to interpret findings
Schünemann 2011 and use GRADEpro to export data from our
review to create a Summary of findings’ table. These tables pro-
vide outcome-specific information concerning the overall quality
of evidence from each study in the comparison, the magnitude
of effect of the interventions, and the sum of available data on
all outcomes we consider important to patient-care and decision
making. We have selected the following main outcomes for inclu-
sion in the Summary of findings’ table.
1. Global state: clinically important overall change
2. Mental state: general symptoms - clinically important
overall change
3. Adverse effects: specific - movement disorders
(extrapyramidal side effects, specifically tardive dyskinesia and
neuroleptic malignant syndrome) - clinically important overall
change
4. Behaviour: specific - aggressive or violent behaviour
5. Leaving the study early: any reason
6. Satisfaction with care: recipients of care or carers - clinically
important change - as defined by each of the studies
7. Cost of care: total direct and indirect costs
If data are unavailable for these prespecified outcomes but are avail-
able for ones that are similar, we will present the closest outcome
to the prespecified one in the table but take this into account when
grading the finding.
Search methods for identification of studies
Electronic searches
The Information Specialist will search the Cochrane Schizophre-
nia Group’s trials register using the following search strategy:
(*chlorpromazine* AND *thiothixene*) in Intervention Field of
STUDY.
The Cochrane Schizophrenia Group’s Trials Register is compiled
by systematic searches of major resources (including AMED,
BIOSIS, CINAHL, Embase, MEDLINE, PsycINFO, PubMed,
and registries of clinical trials) and their monthly updates, hand-
searches, grey literature, and conference proceedings (see the
Group’s Module for further information). There are no language,
date, document type, or publication status limitations for inclu-
sion of records into the register.
Searching other resources
1. Reference searching
We will inspect the references of all identified studies for further
studies.
2. Pharmaceutical companies
We will contact pharmaceutical companies for any unpublished
and published trials.
Data collection and analysis
Selection of studies
Three review authors (PS, BD, and JW) will independently screen
citations from the searches and identify relevant abstracts. One
review author (DC) will independently re-inspect a random 20%
sample of these abstracts to ensure reliability.Where disputes arise,
wewill acquire the full-text article formore detailed scrutiny. Three
review authors (PS, BD, and JW) will then obtain and inspect the
full reports of the abstracts or reports that meet the review criteria.
One review authors, DC, will re-inspect a random 20% of these
full reports in order to ensure reliable selection.Wewill resolve any
disagreement by discussion. We will include studies that meet our
inclusion criteria and report useable data. We will list all studies
excluded after full-text assessment and their reason(s) for exclusion
in a Characteristics of excluded studies’ table. We will illustrate
the study selection process in a PRISMA flow diagram.
Data extraction and management
1. Extraction
Two review authors (PS and BD) will extract data from all in-
cluded studies. In addition, to ensure reliability, review author DC
will independently extract data from a random sample of these
studies, which will comprise 10% of the total. Again, we will dis-
cuss and document any disagreement and, if necessary CEA (see
Acknowledgements) will help clarify issues and we will document
these final decisions.Wewill attempt to extract data presented only
in graphs and figures whenever possible. If studies are multicentre,
where possible, we will extract data relevant to each component
centre separately.
2. Management
2.1 Forms
We will extract data onto standardized, pre-designed, simple
forms.
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2.2 Scale-derived data
We will include continuous data from rating scales only if:
a) the psychometric properties of the measuring instrument have
been described in a peer-reviewed journal (Marshall 2000); and
b) the measuring instrument has not been written or modified by
one of the trial authors for that particular trial.
c) the instrument should be a global assessment of an area of func-
tioning and not subscores which are not, in themselves, validated
or shown to be reliable.
However there are exceptions, we will include subscores from
mental state scales measuring positive and negative symptoms of
schizophrenia.
Ideally the measuring instrument should either be i. a self-report
or ii. completed by an independent rater or relative (not the ther-
apist). We realise that this is not often reported clearly; in the
Description of studies’ section of the review we will note if this
is the case or not.
2.3 Endpoint versus change data
There are advantages of both endpoint and change data: change
data can remove a component of between-person variability from
the analysis; however, calculation of change needs two assessments
(baseline and endpoint) that can be difficult to obtain in unstable
and difficult-to-measure conditions, such as schizophrenia. We
have decided primarily to use endpoint data, and only use change
data if the former are not available. If necessary, we will combine
endpoint and change data in the analysis, as we prefer to use mean
difference (MD) values rather than standardised mean difference
(SMD) values throughout (Higgins 2011).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we will apply the following standards
to relevant continuous data before inclusion.
For endpoint data from studies including fewer than 200 partici-
pants:
a) when a scale starts from the nite number zero, we will subtract
the lowest possible value from the mean, and divide this by the
standard deviation (SD). If this value is lower than one, it strongly
suggests that the data are skewed and we will exclude these data. If
this ratio is higher than one but less than two, there is suggestion
that the data are skewed: we will enter these data and test whether
their inclusion or exclusion would change the results substantially.
If these data do change resultswewill enter as other data’. Finally,
if the ratio is larger than two we will include these data, because it
is less likely that they are skewed (Altman 1996; Higgins 2011).
b) if a scale starts from a positive value (such as the Positive and
Negative Syndrome Scale (PANSS), which can have values from
30 to 210 (Kay 1987)), we will modify the calculation described
above to take the scale starting point into account. In these cases
skewed data are present if 2 SD > (S− Smin), where S is the mean
score and S min’ is the minimum score. We will enter such data
as other data’.
Please note: we will enter all relevant data from studies of more
than 200 participants in the analysis irrespective of the above rules,
because skewed data pose less of a problem in large studies.We will
also enter all relevant change data, as when continuous data are
presented on a scale that includes a possibility of negative values
(such as change data), it is difficult to tell whether or not data are
skewed.
2.5 Common measurement
To facilitate comparison between trials we aim, where relevant, to
convert variables that can be reported in different metrics, such as
days in hospital (mean days per year, per week or per month) to a
common metric (e.g. mean days per month).
2.6 Conversion of continuous to binary
Where possible, we will make efforts to convert outcome mea-
sures to dichotomous data. This can be done by identifying cut-off
points on rating scales and dividing participants accordingly into
clinically improved’ or not clinically improved’. It is generally
assumed that if there is a 50% reduction in a scale-derived score
such as the Brief Psychiatric Rating Scale (BPRS) (Overall 1962),
or the PANSS (Kay 1987), this could be considered as a clinically
significant response (Leucht 2005). If data based on these thresh-
olds are not available, we will use the primary cut-off presented by
the original study authors.
2.7 Direction of graphs
Where possible, we will enter data in such a way that the area to
the left of the line of no effect indicates a favourable outcome for
chlorpromazine and the area to the right of the line of no effect
indicates a favourable outcome for thiothixene. Where keeping
to this makes it impossible to avoid outcome titles with clumsy
double-negatives (e.g. not un-improved’) we will report data
where the left of the line indicates an unfavourable outcome and
note this in the relevant graphs.
Assessment of risk of bias in included studies
Two review authors (PS and BD) will work independently to assess
risk of bias by using criteria described in the Cochrane Handbook
for Systematic Reviews of Interventions to assess trial quality (Higgins
2011a). This set of criteria is based on evidence of associations
between potential overestimation of effect and the level of risk of
bias of the article that may be due to aspects of sequence genera-
tion, allocation concealment, blinding, incomplete outcome data
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and selective reporting, or the way in which these ’domains’ are
reported.
We will note the level of risk of bias in both the text of the review,
Risk of bias’ figures, and the ’Summary of findings’ table(s).
Measures of treatment effect
1. Binary data
For binary outcomes we will calculate a standard estimation of
the risk ratio (RR) and its 95% confidence interval (CI), as it
has been shown that RR is more intuitive than odds ratios (ORs)
(Boissel 1999); and that ORs tend to be interpreted as RRs by
clinicians (Deeks 2002). Although the number needed to treat for
an additional beneficial outcome (NNTB) and the number needed
to treat for an additional harmful outcome (NNTH), with their
CIs, are intuitively attractive to clinicians, they are problematic
to calculate and interpret in meta-analyses (Hutton 2009). For
binary data presented in the Summary of findings’ table(s) we
will, where possible, calculate illustrative comparative risks.
2. Continuous data
For continuous outcomes we will estimate MD between groups.
We prefer not to calculate effect size measures (SMD). However,
if scales of very considerable similarity are used, we will presume
there is a small difference in measurement, and we will calculate
effect size and transform the effect back to the units of one or more
of the specific instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ cluster randomisation’ (such as ran-
domisation by clinician or practice), but analysis and pooling of
clustered data poses problems. Firstly, study authors often fail to
account for intraclass correlation in clustered studies, leading to
a unit-of-analysis error whereby P values are spuriously low, CIs
unduly narrow, and statistical significance overestimated (Divine
1992). This causes type I errors (Bland 1997; Gulliford 1999).
Where clustering has been incorporated into the analysis of pri-
mary studies, we will present these data as if from a non-cluster
randomised study, but adjust for the clustering effect.
Where clustering is not accounted for in primary studies, we will
present data in a table, with a (*) symbol to indicate the presence
of a probable unit of analysis error.We will seek to contact first au-
thors of studies to obtain intraclass correlation coefficients (ICCs)
for their clustered data and to adjust for this by using accepted
methods (Gulliford 1999).
We have sought statistical advice and have been advised that the
binary data from cluster trials presented in a report should be
divided by a design effect’. This is calculated using the mean
number of participants per cluster (m) and the ICC: thus design
effect = 1 + (m − 1) * ICC (Donner 2002). If the ICC is not
reported we will assume it to be 0.1 (Ukoumunne 1999).
If cluster studies have been appropriately analysed and taken ICCs
and relevant data documented in the report into account, synthesis
with other studieswill be possible using the generic inverse variance
technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. This
occurs if an effect (e.g. pharmacological, physiological, or psycho-
logical) of the treatment in the first phase is carried over to the sec-
ond phase. As a consequence, participants can differ significantly
from their initial state at entry to the second phase, despite a wash-
out phase. For the same reason cross-over trials are not appropriate
if the condition of interest is unstable (Elbourne 2002). As both
carry-over and unstable conditions are very likely in severe men-
tal illness, we will only use data from the first phase of cross-over
studies.
3. Studies with multiple treatment groups
Where a study involves more than two treatment arms, if relevant,
we will present the additional treatment arms in comparisons. If
data are binary we will simply add these and combine within the
two-by-two table. If data are continuous we will combine data
following the formula in the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011). Where additional treatment
arms are irrelevant, we will not reproduce these data.
Dealing with missing data
1. Overall loss of credibility
Loss to follow-up is a reality of RCTs (Xia 2009), when loss to
follow-up becomes considerable this limits the quality of the study.
If trials have missing data for more than 50% of participants in
the arms of interest in the trial (those treated with chlorpromazine
or thiothixene), we will report this. We will penalise studies that
have a loss to follow-up rate of above 25% accordingly by altering
their ratings of quality in the ’Summary of findings’ table.
2. Binary
In the case where attrition for a binary outcome is between 0%
and 50% and where these data are not clearly described, we will
present data on a ’once-randomised-always-analyse’ basis (an in-
tention-to-treat analysis (ITT)). Those leaving the study early are
8Chlorpromazine versus thiothixene for people with schizophrenia (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
all assumed to have the same rates of negative outcome as those
who completed.We will use the rate of those who stay in the study
- in that particular arm of the trial - and apply this also to those
who did not. We will undertake a sensitivity analysis testing how
prone the primary outcomes are to change when data only from
people who complete the study to that point are compared to the
intention-to-treat analysis using the above assumptions.
3. Continuous
3.1 Attrition
We will use data where attrition for a continuous outcome is be-
tween 0% and 50%, and data only from people who complete the
study to that point are reported.
3.2 SDs
If SDs are not reported, where there are missing measures of vari-
ance for continuous data, but an exact standard error (SE) and
CIs available for group means, and either P value or t value avail-
able for differences in mean, we can calculate SDs according to
the rules described in the Cochrane Handbook for Systematic Re-
views of Interventions (Deeks 2011).When only the SE is reported,
SDs are calculated by the formula SD = SE *
√
(n). The Cochrane
Handbook for Systematic Reviews of Interventions presents detailed
formulae for estimating SDs from P, t, or F values, CIs, ranges, or
other statistics (Deeks 2011).
3.3 Assumptions about participants who left the trials early
or were lost to follow-up
Various methods are available to account for participants who left
the trials early or were lost to follow-up. Some trials just present
the results of study completers; others use the method of last ob-
servation carried forward (LOCF); while more recently, methods
such as multiple imputation or mixed-effects models for repeated
measurements (MMRM) have become more of a standard. While
the latter methods seem to be somewhat better than LOCF (Leon
2006), we feel that the high percentage of participants leaving the
studies early and differences between groups in their reasons for
doing so is often the core problem in randomised schizophrenia
trials. We will therefore not exclude studies based on the statistical
approach used. However, by preference we will use the more so-
phisticated approaches, i.e. we will prefer to use MMRM or mul-
tiple-imputation to LOCF, and we will only present completer
analyses if some kind of ITT data are not available at all.Moreover,
we will address this issue in the Incomplete outcome data’ item
of the Risk of bias’ tool.
Assessment of heterogeneity
1. Clinical heterogeneity
Wewill consider all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We will simply in-
spect all studies for participants who are clearly outliers or situ-
ations that we had not predicted would arise and, where found,
discuss such situations or participant groups.
2. Methodological heterogeneity
Wewill consider all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity.We will sim-
ply inspect all studies for clearly outlying methods which we had
not predicted would arise and discuss any such methodological
outliers.
3. Statistical heterogeneity
3.1 Visual inspection
We will inspect graphs visually to investigate the possibility of
statistical heterogeneity.
3.2 Employing the I² statistic
We will investigate heterogeneity between studies by considering
the I² statistic alongside the Chi² P value. The I² statistic provides
an estimate of the percentage of inconsistency thought to be due
to chance (Higgins 2003). The importance of the observed value
of I² depends on the magnitude and direction of effects as well as
the strength of evidence for heterogeneity (e.g. P value from Chi²
test, or a CI for I² statistic value). We will interpret an I² statistic
value estimate of greater than or equal to 50% and accompanied
by a statistically significant Chi² statistic as evidence of substantial
heterogeneity (Section 9.5.2 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions) (Deeks 2011). When we iden-
tify substantial levels of heterogeneity in the primary outcome, we
will explore the reasons for heterogeneity (Subgroup analysis and
investigation of heterogeneity).
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Section 10.1 of the Cochrane Handbook for
Systemic Reviews of Interventions (Sterne 2011).
9Chlorpromazine versus thiothixene for people with schizophrenia (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1. Protocol versus full study
Wewill try to locate protocols of included randomised trials. If the
protocol is available, we will compare outcomes in the protocol
and in the published report. If the protocol is unavailable, we will
compare outcomes listed in the methods section of the trial report
with actually reported results.
2. Funnel plot
We are aware that funnel plots may be useful in investigating
reporting biases but are of limited power to detect small-study
effects. We will not use funnel plots for outcomes where there are
10 or fewer studies, or where all studies are of similar size. In other
cases, where funnel plots are possible, we will seek statistical advice
in their interpretation.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies, even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model: it puts added weight onto small studies,
which often are the most biased ones. Depending on the direction
of effect, these studies can either inflate or deflate the effect size.
We will use a fixed-effect model for all analyses.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
1.1 Primary outcomes
We anticipate no subgroup analysis.
2. Investigation of heterogeneity
We will report if inconsistency is high. Firstly, we will investigate
whether data have been entered correctly. Secondly, if data are cor-
rect, we will inspect the graph visually and remove outlying studies
successively to see if homogeneity is restored. For this Cochrane
Review we have decided that should this occur with data con-
tributing to the summary finding of no more than 10% of the
total weighting, we will present the data. If not, we will not pool
these data and will discuss any issues. We know of no supporting
research for this 10% cut-off but are investigating use of predic-
tion intervals as an alternative to this unsatisfactory state.
When unanticipated clinical or methodological heterogeneity is
obvious we will simply state hypotheses regarding these for future
reviews or versions of this review.Wedonot anticipate undertaking
analyses relating to these.
Sensitivity analysis
If there are substantial differences in the direction or precision of
effect estimates in any of the sensitivity analyses listed below, we
will not add data from the lower-quality studies to the results of
the higher-quality trials, but will present these data within a sub-
category. If their inclusion does not result in a substantive differ-
ence, they will remain in the analyses.
1. Implication of randomisation
If trials are described in some way as to imply randomisation, for
the primary outcomes, we will pool data from the implied trials
with trials that are randomised.
2. Assumptions for lost binary data
Where we have to make assumptions regarding people lost to fol-
low-up (see Dealing with missing data), we will compare the find-
ings of the primary outcomes when we use our assumption com-
pared with completer data only. If there is a substantial difference,
we will report results and discuss them but continue to employ
our assumption.
Where we have to make assumptions regarding missing SD values
(see Dealing with missing data), we will compare the findings on
primary outcomes when we use our assumption compared with
completer data only.Wewill undertake a sensitivity analysis testing
how prone results are to change when completer’ data only are
compared to the imputed data using the above assumption. If there
is a substantial difference, we will report results and discuss them
but continue to employ our assumption.
3. Risk of bias
We will analyse the effects of excluding trials that are at high risk
of bias across one or more of the domains (see Assessment of risk
of bias in included studies) for the meta-analysis of the primary
outcome.
4. Imputed values
We will also undertake a sensitivity analysis to assess the effects of
including data from trials where we use imputed values for ICC
in calculating the design effect in cluster-randomised trials.
5. Fixed-effect and random-effects
We will synthesise data using a fixed-effect model. However, we
will also synthesise data for the primary outcome using a random-
effects model to evaluate whether this alters the significance of the
results.
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A D D I T I O N A L T A B L E S
Table 1. Thiothixene prescription products
Approved prescription products
Name Dose available Company Country
Navane Capsule 5mg ERFA 2012 Canada
Approved generic prescription products
Name Dose available Company Country
Thiothixene capsule 1 mg/2 mg/5 mg/10 mg Sandoz Inc. (Drugbank 2017) USA
Thiothixene capsule 1 mg/2 mg/5 mg/10 mg Mylan Pharmaceuticals Inc. (
Drugbank 2017)
USA
Thiothixene capsule 1 mg/2 mg/5 mg/10 mg REMEDYREPACK Inc.
(Drugbank 2017)
USA
Thiothixene capsule 5 mg Carilion Materials Management (
Drugbank 2017)
USA
Thiothixene capsule 5 mg Rebel Distributors Corp
(Drugbank 2017)
USA
Thiothixene capsule 10 mg Florida DOH Central Pharmacy (
Drugbank 2017)
USA
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Table 2. Thiothixene prescription details by country
Prescription details by country
Country of prescriber Total number of prescribers Total number of patients Total number of prescriptions
USA1 16,149 19,085 156,000
1USA Medicaid claims 2013 (ProPublica)
Table 3. Cochrane Reviews of chlorpromazine
Title Reference Publication s tage
Acetophenazine versus chlorpromazine for
schizophrenia
Bazrafshan 2015 Protocol
Aripiprazole versus chlorpromazine for
people with schizophrenia and schizophre-
nia-like psychoses
Bhattacharjee 2016 Protocol
Chlorpromazine versus clotiapine for
schizophrenia
Mazhari 2017 Full review
Haloperidol versus chlorpromazine for
schizophrenia
Leucht 2008 Full review
Chlorpromazine versus metiapine for
schizophrenia
Zare 2017 Full review
Chlorpromazine versus penfluridol for
schizophrenia
Khalili 2015 Protocol
Chlorpromazine versus piperacetazine for
schizophrenia
Eslami Shahrbabaki 2015 Protocol
Chlorpromazine versus placebo for
schizophrenia
Adams 2014 Full review
Chlorpromazine versus reserpine for
schizophrenia
Nur 2016 Full review
Chlorpromazine versus pimozide Registered title
Cessation of medication for people with
schizophrenia already stable on chlorpro-
mazine
Almerie 2007 Full review
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Table 3. Cochrane Reviews of chlorpromazine (Continued)
Chlorpromazine versus atypical antipsy-
chotic drugs for schizophrenia
Saha 2016 Full review
Chlorpromazine dose for people with
schizophrenia
Dudley 2017 Full review
Chlorpromazine for psychosis induced ag-
gression or agitation
Ahmed 2010 Full review
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